Humacyte Inc [NASDAQ: HUMA] closed the trading session at $9.10.
The stocks have a year to date performance of 220.42 percent and weekly performance of 20.37 percent. The stock has been moved at 250.00 percent over the last six months. The stock has performed 132.14 percent around the most recent 30 days and changed 109.20 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 1.84M shares, HUMA reached to a volume of 8149193 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Humacyte Inc [HUMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $8.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 11, 2023. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $2.75 to $3.50. The new note on the price target was released on August 14, 2023, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise to $6, while Cantor Fitzgerald analysts kept a Overweight rating on HUMA stock. On May 16, 2022, analysts decreased their price target for HUMA shares from 10 to 4.
The Average True Range (ATR) for Humacyte Inc is set at 0.61 The Price to Book ratio for the last quarter was 41.44, with the Price to Cash per share for the same quarter was set at 0.97.
HUMA stock trade performance evaluation
Humacyte Inc [HUMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.37. With this latest performance, HUMA shares gained by 132.14% in over the last four-week period, additionally plugging by 250.00% over the last 6 months – not to mention a rise of 157.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HUMA stock in for the last two-week period is set at 87.30, with the RSI for the last a single of trading hit 89.20, and the three-weeks RSI is set at 84.70 for Humacyte Inc [HUMA]. The present Moving Average for the last 50 days of trading for this stock 4.49, while it was recorded at 7.73 for the last single week of trading, and 3.42 for the last 200 days.
Humacyte Inc [HUMA]: An insightful look at the core fundamentals
Humacyte Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.37 and a Current Ratio set at 8.37.
Humacyte Inc [HUMA]: Institutional Ownership
The top three institutional holders of HUMA stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in HUMA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in HUMA stock with ownership which is approximately 5.8386%.
